Features and Outcomes of Microcrystalline Arthritis Treated by Biologics: A Retrospective Study.
Anti-IL-1
Biologic
Calcium pyrophosphate crystal deposition
Crystal-associated arthritis
Gout
Journal
Rheumatology and therapy
ISSN: 2198-6576
Titre abrégé: Rheumatol Ther
Pays: England
ID NLM: 101674543
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
14
04
2021
accepted:
10
06
2021
pubmed:
5
7
2021
medline:
5
7
2021
entrez:
4
7
2021
Statut:
ppublish
Résumé
The usual treatments for crystal-associated arthritis are sometimes contraindicated; thus, new therapies against interleukin-1beta (IL-1) have been developed. We evaluated the characteristics of patients who received biological treatment for crystal-associated arthritis. We conducted a multicentric retrospective observational study in six rheumatology units in western France. Patients receiving a biological treatment for crystal-associated arthritis between 1 January 2010 and 31 December 2018 were included. Improvement was defined as at least a 50% decrease in the count of synovitis and C-reactive protein level. Forty-six patients were included: 31 (67.4%) were treated for gouty arthritis, and 15 (32.6%) for calcium pyrophosphate crystal deposition disease (CCPD). The first biotherapy used was anakinra for 14 patients (93.3%) with CCPD and 31 patients (100.0%) with gout. The first biotherapy course was more efficient in treating gout than in treating CCPD, with success in 28 patients (90.3%) and 5 patients (35.7%), respectively (p = 0.001). Six patients (42.9%) with CCPD stopped their first biotherapy course because of side effects. Among the patients with gout, urate-lowering therapy was more frequently used after (100%) than before the first biotherapy course (67.7%) (p = 0.002). Anakinra was prescribed for cases of refractory crystal-associated arthritis or cases with contraindications for usual treatments. The efficacy of anakinra in treating CCPD was not obvious. Patients with CCPD had more side effects. The biotherapy was introduced with a long-term objective, while anti-IL-1 therapies are approved for acute crises only.
Identifiants
pubmed: 34218418
doi: 10.1007/s40744-021-00335-7
pii: 10.1007/s40744-021-00335-7
pmc: PMC8380607
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1241-1253Informations de copyright
© 2021. The Author(s).
Références
Choi H. Epidemiology of crystal arthropathy. Rheum Dis Clin North Am. 2006;32(2):255–73. https://doi.org/10.1016/j.rdc.2006.03.002 (v).
doi: 10.1016/j.rdc.2006.03.002
pubmed: 16716879
Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29–42. https://doi.org/10.1136/annrheumdis-2016-209707 .
doi: 10.1136/annrheumdis-2016-209707
Khanna D, Khanna PP, FitzGerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout part II: therapy and anti-inflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2012;64(10):1447–61. https://doi.org/10.1002/acr.21773 .
doi: 10.1002/acr.21773
Latourte A, Pascart T, Flipo R-M, et al. 2020 Recommendations from the French Society of Rheumatology for the management of gout: management of acute flares. Joint Bone Spine. 2020;87(5):387–93. https://doi.org/10.1016/j.jbspin.2020.05.001 .
doi: 10.1016/j.jbspin.2020.05.001
pubmed: 32422339
Keenan RT, O’Brien WR, Lee KH, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011;124(2):155–63. https://doi.org/10.1016/j.amjmed.2010.09.012 .
doi: 10.1016/j.amjmed.2010.09.012
pubmed: 21295195
Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237–41. https://doi.org/10.1038/nature04516 .
doi: 10.1038/nature04516
pubmed: 16407889
Schlesinger N, De Meulemeester M, Pikhlak A, et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat gouty arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res Ther. 2011;13(2):R53. https://doi.org/10.1186/ar3297 .
doi: 10.1186/ar3297
pubmed: 21439048
pmcid: 3132043
Ottaviani S, Moltó A, Ea H-K, et al. Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. Arthritis Res Ther. 2013;15(5):R123. https://doi.org/10.1186/ar4303 .
doi: 10.1186/ar4303
pubmed: 24432362
pmcid: 3978950
Nunes EAS, Rosseti AG, Ribeiro DS, Santiago M. Gout initially mimicking rheumatoid arthritis and later cervical spine involvement. Case Rep Rheumatol. 2014. https://doi.org/10.1155/2014/357826 .
doi: 10.1155/2014/357826
pubmed: 25574418
pmcid: 4276112
Neogi T, Jansen TLTA, Dalbeth N, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol Hoboken NJ. 2015;67(10):2557–68. https://doi.org/10.1002/art.39254 .
doi: 10.1002/art.39254
Devauchelle-Pensec V, Berthelot JM, Jousse S, et al. Performance of hand radiographs in predicting the diagnosis in patients with early arthritis. J Rheumatol. 2006;33(8):1511–5.
pubmed: 16783864
Solomon DH, Glynn RJ, MacFadyen JG, et al. Relationship of interleukin-1β blockade with incident gout and serum uric acid levels: exploratory analysis of a randomized controlled trial. Ann Intern Med. 2018;169(8):535–42. https://doi.org/10.7326/M18-1167 .
doi: 10.7326/M18-1167
pubmed: 30242335
Pascart T, Latourte A, Flipo R-M, et al. recommendations from the French Society of Rheumatology for the management of gout: urate-lowering therapy. Joint Bone Spine. 2020. https://doi.org/10.1016/j.jbspin.2020.05.002 .
doi: 10.1016/j.jbspin.2020.05.002
pubmed: 32422339
Schlesinger N, Mysler E, Lin H-Y, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis. 2011;70(7):1264–71. https://doi.org/10.1136/ard.2010.144063 .
doi: 10.1136/ard.2010.144063
pubmed: 21540198
Loustau C, Rosine N, Forien M, et al. Effectiveness and safety of anakinra in gout patients with stage 4–5 chronic kidney disease or kidney transplantation: a multicentre, retrospective study. Joint Bone Spine. 2018;85(6):755–60. https://doi.org/10.1016/j.jbspin.2018.03.015 .
doi: 10.1016/j.jbspin.2018.03.015
pubmed: 29654950
Yang B-B, Baughman S, Sullivan JT. Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin Pharmacol Ther. 2003;74(1):85–94. https://doi.org/10.1016/S0009-9236(03)00094-8 .
doi: 10.1016/S0009-9236(03)00094-8
pubmed: 12844139
Ea H-K, Chobaz V, Nguyen C, et al. Pathogenic role of basic calcium phosphate crystals in destructive arthropathies. PLoS ONE. 2013;8(2): e57352. https://doi.org/10.1371/journal.pone.0057352 .
doi: 10.1371/journal.pone.0057352
pubmed: 23468973
pmcid: 3585350
Omoigui S, Irene S. Subcutaneous injection of anakinra in patients with shoulder pain due to rotator cuff tendonitis and subacromial bursitis. Pain Med Malden Mass. 2004;5(2):229–30. https://doi.org/10.1111/j.1526-4637.2004.04022.x .
doi: 10.1111/j.1526-4637.2004.04022.x
Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012;71(11):1839–48. https://doi.org/10.1136/annrheumdis-2011-200908 .
doi: 10.1136/annrheumdis-2011-200908
pubmed: 22586173
Janssen CA, Oude Voshaar MAH, Vonkeman HE, et al. Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial. Rheumatol Oxf Engl. 2019. https://doi.org/10.1093/rheumatology/key402 .
doi: 10.1093/rheumatology/key402
Klück V, Jansen TLTA, Janssen M, et al. Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial. Lancet Rheumatol. 2020;2(5):e270–80. https://doi.org/10.1016/S2665-9913(20)30065-5 .
doi: 10.1016/S2665-9913(20)30065-5
pubmed: 33005902
pmcid: 7523621
Zhang W, Doherty M, Pascual E, et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis. 2011;70(4):571–5. https://doi.org/10.1136/ard.2010.139360 .
doi: 10.1136/ard.2010.139360
pubmed: 21257614
Ottaviani S, Brunier L, Sibilia J, et al. Efficacy of anakinra in calcium pyrophosphate crystal-induced arthritis: a report of 16 cases and review of the literature. Joint Bone Spine. 2013;80(2):178–82. https://doi.org/10.1016/j.jbspin.2012.07.018 .
doi: 10.1016/j.jbspin.2012.07.018
pubmed: 23022422
Thomas M, Forien M, Palazzo E, Dieudé P, Ottaviani S. Efficacy and tolerance of anakinra in acute calcium pyrophosphate crystal arthritis: a retrospective study of 33 cases. Clin Rheumatol. 2019;38(2):425–30. https://doi.org/10.1007/s10067-018-4272-2 .
doi: 10.1007/s10067-018-4272-2
pubmed: 30145636
Liew JW, Gardner GC. Use of anakinra in hospitalized patients with crystal-associated arthritis. J Rheumatol. 2019;46(10):1345–9. https://doi.org/10.3899/jrheum.181018 .
doi: 10.3899/jrheum.181018
pubmed: 30647192
Pascart T, Norberciak L, Ea H-K, Graf S, Guggenbuhl P, Lioté F. Difficult-to-treat gout flares: eligibility for interleukin-1 inhibition in private practice is uncommon according to current EMA approval. Rheumatol Oxf Engl. 2019;58(12):2181–7. https://doi.org/10.1093/rheumatology/kez203 .
doi: 10.1093/rheumatology/kez203
Bardin T, Bouée S, Clerson P, et al. Prevalence of gout in the adult population of France. Arthritis Care Res. 2016;68(2):261–6. https://doi.org/10.1002/acr.22660 .
doi: 10.1002/acr.22660